Early post-discharge mortality in CAP : frequency, risk factors and a prediction tool
© 2022. The Author(s)..
There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822-0.839, p < 0.001) for prediction of post-discharge mortality. Early post-discharge deaths account for ¼ of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT02139163.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 41(2022), 4 vom: 08. Apr., Seite 621-630 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Glöckner, Verena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Study |
|---|
| Anmerkungen: |
Date Completed 22.03.2022 Date Revised 31.05.2022 published: Print-Electronic ClinicalTrials.gov: NCT02139163 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-022-04416-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336696485 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336696485 | ||
| 003 | DE-627 | ||
| 005 | 20231225232728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-022-04416-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336696485 | ||
| 035 | |a (NLM)35137301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Glöckner, Verena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early post-discharge mortality in CAP |b frequency, risk factors and a prediction tool |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02139163 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822-0.839, p < 0.001) for prediction of post-discharge mortality. Early post-discharge deaths account for ¼ of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT02139163 | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Community-acquired pneumonia | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Post-discharge | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Pletz, Mathias W |e verfasserin |4 aut | |
| 700 | 1 | |a Rohde, Gernot |e verfasserin |4 aut | |
| 700 | 1 | |a Rupp, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Witzenrath, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Barten-Neiner, Grit |e verfasserin |4 aut | |
| 700 | 1 | |a Kolditz, Martin |e verfasserin |4 aut | |
| 700 | 0 | |a CAPNETZ Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Dreher, M |e investigator |4 oth | |
| 700 | 1 | |a Cornelissen, C |e investigator |4 oth | |
| 700 | 1 | |a Knüppel, W |e investigator |4 oth | |
| 700 | 1 | |a Stolz, D |e investigator |4 oth | |
| 700 | 1 | |a Suttorp, N |e investigator |4 oth | |
| 700 | 1 | |a Creutz, P |e investigator |4 oth | |
| 700 | 1 | |a Witzenrath, M |e investigator |4 oth | |
| 700 | 1 | |a Mikolajewska, A |e investigator |4 oth | |
| 700 | 1 | |a le Claire, A |e investigator |4 oth | |
| 700 | 1 | |a Benzke, M |e investigator |4 oth | |
| 700 | 1 | |a Bauer, T |e investigator |4 oth | |
| 700 | 1 | |a Krieger, D |e investigator |4 oth | |
| 700 | 1 | |a Prediger, M |e investigator |4 oth | |
| 700 | 1 | |a Schmager, S |e investigator |4 oth | |
| 700 | 1 | |a Kolditz, M |e investigator |4 oth | |
| 700 | 1 | |a Schulte-Hubbert, B |e investigator |4 oth | |
| 700 | 1 | |a Langner, S |e investigator |4 oth | |
| 700 | 1 | |a Rohde, G |e investigator |4 oth | |
| 700 | 1 | |a Degen, O |e investigator |4 oth | |
| 700 | 1 | |a Hüfner, A |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, C |e investigator |4 oth | |
| 700 | 1 | |a Welte, T |e investigator |4 oth | |
| 700 | 1 | |a Freise, J |e investigator |4 oth | |
| 700 | 1 | |a Barten-Neiner, G |e investigator |4 oth | |
| 700 | 1 | |a Nawrocki, M |e investigator |4 oth | |
| 700 | 1 | |a Fuge, I |e investigator |4 oth | |
| 700 | 1 | |a Freise, J |e investigator |4 oth | |
| 700 | 1 | |a Naim, J |e investigator |4 oth | |
| 700 | 1 | |a Kröner, W |e investigator |4 oth | |
| 700 | 1 | |a Illig, T |e investigator |4 oth | |
| 700 | 1 | |a Klopp, N |e investigator |4 oth | |
| 700 | 1 | |a Kroegel, C |e investigator |4 oth | |
| 700 | 1 | |a Moeser, A |e investigator |4 oth | |
| 700 | 1 | |a Pletz, M |e investigator |4 oth | |
| 700 | 1 | |a Schleenvoigt, B |e investigator |4 oth | |
| 700 | 1 | |a Bahrs, C |e investigator |4 oth | |
| 700 | 1 | |a Drömann, D |e investigator |4 oth | |
| 700 | 1 | |a Parschke, P |e investigator |4 oth | |
| 700 | 1 | |a Franzen, K |e investigator |4 oth | |
| 700 | 1 | |a Rupp, J |e investigator |4 oth | |
| 700 | 1 | |a Käding, N |e investigator |4 oth | |
| 700 | 1 | |a Wouters, M |e investigator |4 oth | |
| 700 | 1 | |a Walraven, K |e investigator |4 oth | |
| 700 | 1 | |a Braeken, D |e investigator |4 oth | |
| 700 | 1 | |a Spinner, C |e investigator |4 oth | |
| 700 | 1 | |a Buschmann, H |e investigator |4 oth | |
| 700 | 1 | |a Zaruchas, A |e investigator |4 oth | |
| 700 | 1 | |a Schaberg, T |e investigator |4 oth | |
| 700 | 1 | |a Hering, I |e investigator |4 oth | |
| 700 | 1 | |a Albrich, W |e investigator |4 oth | |
| 700 | 1 | |a Waldeck, F |e investigator |4 oth | |
| 700 | 1 | |a Rassouli, F |e investigator |4 oth | |
| 700 | 1 | |a Baldesberger, S |e investigator |4 oth | |
| 700 | 1 | |a Panning, M |e investigator |4 oth | |
| 700 | 1 | |a Wallner, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 41(2022), 4 vom: 08. Apr., Seite 621-630 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:4 |g day:08 |g month:04 |g pages:621-630 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-022-04416-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 4 |b 08 |c 04 |h 621-630 | ||